<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7090514/results/search/disease/results.xml">
  <result pre="Viewpoint Pharmaceutical care recommendations for antiviral treatments in children with" exact="coronavirus disease" post="2019 WangYan1ZhuLi-Qinzlq0713@aliyun.com2[1], grid.417022.20000 0004 1772 3918Department of Pharmacy, Tianjin"/>
  <result pre="Pharmaceutical care recommendations for antiviral treatments in children with coronavirus" exact="disease" post="2019 WangYan1ZhuLi-Qinzlq0713@aliyun.com2[1], grid.417022.20000 0004 1772 3918Department of Pharmacy, Tianjin"/>
  <result pre="Hospital, [2], grid.417024.40000 0004 0605 6814Department of Pharmacy, Tianjin First" exact="Central" post="Hospital, epub: 2020-3-314received: 2020-2-20accepted: 2020-3-2(C) , This article is"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="exact efficacy are recommended to be used in children with" exact="coronavirus disease" post="2019 (COVID-19). Interim Guidance for Diagnosis and Treatment (the"/>
  <result pre="efficacy are recommended to be used in children with coronavirus" exact="disease" post="2019 (COVID-19). Interim Guidance for Diagnosis and Treatment (the"/>
  <result pre="8–10 sprays/day for 5–7 days Contraindication: CrCl &amp;lt; 50 mL/min; histories of" exact="mental illness," post="severe or unstable heart disease, or aplastic anemia LPVr"/>
  <result pre="Contraindication: CrCl &amp;lt; 50 mL/min; histories of mental illness, severe or unstable" exact="heart" post="disease, or aplastic anemia LPVr China: OS ≥ 6"/>
  <result pre="histories of mental illness, severe or unstable heart disease, or" exact="aplastic anemia" post="LPVr China: OS ≥ 6 months, T ≥ 2"/>
  <result pre="of mental illness, severe or unstable heart disease, or aplastic" exact="anemia" post="LPVr China: OS ≥ 6 months, T ≥ 2"/>
  <result pre="mg/time, twice daily for 1–2 weeks Contraindication: patients with severe" exact="hepatic insufficiency" post="Not be recommended: children with jaundice Ribavirin China: oral"/>
  <result pre="be recommended: CrCl &amp;lt; 50 mL/min Should be discontinued: SCr &amp;gt; 2 mg/dL Warning:" exact="hemolytic anemia" post="CD Using with caution No recommendation Acute poisoning is"/>
  <result pre="recommended: CrCl &amp;lt; 50 mL/min Should be discontinued: SCr &amp;gt; 2 mg/dL Warning: hemolytic" exact="anemia" post="CD Using with caution No recommendation Acute poisoning is"/>
  <result pre="mg/dL Warning: hemolytic anemia CD Using with caution No recommendation" exact="Acute" post="poisoning is usually fatal with a dose of 50"/>
  <result pre="liver dysfunction IFN-α interferon-α, LPVr lopinavir/ritonavir, CD chloroquine diphosphate, COVID-19" exact="coronavirus disease" post="2019, CrCl creatinine clearance, SCr serum creatinine, OS oral"/>
  <result pre="dysfunction IFN-α interferon-α, LPVr lopinavir/ritonavir, CD chloroquine diphosphate, COVID-19 coronavirus" exact="disease" post="2019, CrCl creatinine clearance, SCr serum creatinine, OS oral"/>
  <result pre="a broad-spectrum antiviral drug, which could inhibit the synthesis of" exact="viral" post="RNA and inhibit viral replication and spread. IFN-α, combined"/>
  <result pre="which could inhibit the synthesis of viral RNA and inhibit" exact="viral" post="replication and spread. IFN-α, combined with ribavirin, which could"/>
  <result pre="replication and spread. IFN-α, combined with ribavirin, which could reduce" exact="viral" post="replication, moderated the host response and improved clinical outcome"/>
  <result pre="nebulization or spray are commonly used in children for treating" exact="bronchiolitis" post="[3, 4], herpes angina [5, 6], hand-foot-mouth disease [7,"/>
  <result pre="are commonly used in children for treating bronchiolitis [3, 4]," exact="herpes" post="angina [5, 6], hand-foot-mouth disease [7, 8], etc. In"/>
  <result pre="for treating bronchiolitis [3, 4], herpes angina [5, 6], hand-foot-mouth" exact="disease" post="[7, 8], etc. In the experts' consensus statements, it"/>
  <result pre="of contact with suspected infected patients or those with only" exact="upper" post="respiratory tract symptoms in the early phase. One to"/>
  <result pre="contact with suspected infected patients or those with only upper" exact="respiratory" post="tract symptoms in the early phase. One to two"/>
  <result pre="days. Intramuscular injection of high-dose IFN-α (&amp;gt; 2 μg/kg/time) could cause" exact="myelosuppression" post="in children [10]. Overdose of IFN-α also could cause"/>
  <result pre="[10]. Overdose of IFN-α also could cause liver enzyme abnormalities," exact="renal failure," post="bleeding, etc. It should be cautious while prescribing for"/>
  <result pre="prohibited. IFN-α is also contraindicated in children with histories of" exact="mental illness," post="severe or unstable heart disease, or aplastic anemia. IFN-α"/>
  <result pre="in children with histories of mental illness, severe or unstable" exact="heart" post="disease, or aplastic anemia. IFN-α nebulization should be used"/>
  <result pre="histories of mental illness, severe or unstable heart disease, or" exact="aplastic anemia." post="IFN-α nebulization should be used with caution in neonates"/>
  <result pre="be used with caution in patients with mild to moderate" exact="hepatic insufficiency," post="and contraindicated in patients with severe hepatic insufficiency. In"/>
  <result pre="to moderate hepatic insufficiency, and contraindicated in patients with severe" exact="hepatic insufficiency." post="In addition, LPVr could cause increased PR interval, second-"/>
  <result pre="[18]. LPVr should be used with caution in children with" exact="congenital" post="QT interval extension syndrome or hypokalemia. The most common"/>
  <result pre="used with caution in children with congenital QT interval extension" exact="syndrome" post="or hypokalemia. The most common adverse reactions of LPVr"/>
  <result pre="or hypokalemia. The most common adverse reactions of LPVr include" exact="diarrhea" post="(adults 19.5%; children 12%), vomiting (adults 6.8%; children 21%),"/>
  <result pre="reactions of ribavirin in children include fever (80%), headache (62%)," exact="neutropenia" post="(33%), fatigue (30%), etc. [20]. Ribavirin should be noted"/>
  <result pre="cells and can be largely accumulated, which could lead to" exact="hemolytic anemia" post="[21, 22]. Large doses of ribavirin could cause decreased"/>
  <result pre="and can be largely accumulated, which could lead to hemolytic" exact="anemia" post="[21, 22]. Large doses of ribavirin could cause decreased"/>
  <result pre="Large doses of ribavirin could cause decreased hemoglobin and serious" exact="heart" post="damage. Children with heart diseases should be suggested to"/>
  <result pre="could cause decreased hemoglobin and serious heart damage. Children with" exact="heart" post="diseases should be suggested to avoid using ribavirin. If"/>
  <result pre="etc. CD has shown apparent efficacy in treating COVID-19 in" exact="adult" post="clinical trials [23]. CD is available in oral tablets"/>
  <result pre="no dosage recommendation of CD in COVID-19 children so far." exact="Acute" post="poisoning of CD is usually fatal with a dose"/>
  <result pre="children. CD should be used with caution in patients with" exact="heart" post="diseases, liver or kidney dysfunction, hematoporphyria, mental illness. There"/>
  <result pre="in patients with heart diseases, liver or kidney dysfunction, hematoporphyria," exact="mental illness." post="There are mild adverse reactions of CD in treating"/>
  <result pre="At higher doses of CD, the main adverse reaction is" exact="ocular" post="toxicity, which could affect vision. If eye discomfort or"/>
  <result pre="reaction is ocular toxicity, which could affect vision. If eye" exact="discomfort" post="or visual abnormality occurs, CD should be discontinued. Other"/>
  <result pre="ocular toxicity, which could affect vision. If eye discomfort or" exact="visual" post="abnormality occurs, CD should be discontinued. Other adverse reactions"/>
  <result pre="should be discontinued. Other adverse reactions of CD include arrhythmia," exact="drug-induced psychosis," post="leukopenia, etc. CD is mainly metabolized by liver and"/>
  <result pre="etc. CD is mainly metabolized by liver and the burden" exact="of liver" post="could be aggravated while combining with the other drugs"/>
  <result pre="streptomycin, gentamicin, etc.). Combination of CD with heparin could increase" exact="bleeding" post="risk. For the patients with digitalization, CD could cause"/>
  <result pre="patients with liver dysfunction. Adverse reactions include nausea, diarrhea, dizziness," exact="elevated serum" post="aminotransferase, etc. The average plasma protein binding (PB) rate"/>
  <result pre="3.ShangXYHuangYLiuEMChenQCaoLLuMet al.A multicenter clinical study on the treatment for children's" exact="acute" post="bronchiolitis by nebulized recombinant human interferon α1bChin J Pract"/>
  <result pre="al.A multicenter clinical study on the treatment for children's acute" exact="bronchiolitis" post="by nebulized recombinant human interferon α1bChin J Pract Pediatr201429840844"/>
  <result pre="human normal immunoglobulin on serum cytokine and immunoglobulins levels in" exact="bronchiolitis" post="childrenChin J Hosp Pharm.201838403406 5.ZhongQLZhengYWYanJJDengYFTangLCuiZLet al.The contrast observation of"/>
  <result pre="safety of interferon nebulization and ribavirin in the treatment of" exact="infantile" post="herpes anginaChin Med Pharm201778082 6.LinYHuYYLinZEvaluation of efficacy and safety"/>
  <result pre="of interferon nebulization and ribavirin in the treatment of infantile" exact="herpes" post="anginaChin Med Pharm201778082 6.LinYHuYYLinZEvaluation of efficacy and safety of"/>
  <result pre="of hand, foot, and mouth disease: a multicenter, randomized, double" exact="blind" post="trialArch Virol20161613073308010.1007/s00705-016-3012-727518403 9.ShenKLYangYWangTZhaoDJiangYJinRet al.Diagnosis, treatment, and prevention of 2019"/>
  <result pre="trialArch Virol20161613073308010.1007/s00705-016-3012-727518403 9.ShenKLYangYWangTZhaoDJiangYJinRet al.Diagnosis, treatment, and prevention of 2019 novel" exact="coronavirus infection" post="in children: experts' consensus statementWorld J Pediatr202010.1007/s12519-020-00343-732112336 10.ShenKLShangYXZhangGCXuBPFuZCaoLet al.Expert"/>
  <result pre="Virol20161613073308010.1007/s00705-016-3012-727518403 9.ShenKLYangYWangTZhaoDJiangYJinRet al.Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: experts' consensus statementWorld J Pediatr202010.1007/s12519-020-00343-732112336 10.ShenKLShangYXZhangGCXuBPFuZCaoLet al.Expert"/>
  <result pre="injection. https://drugs.dxy.cn/drug/153953/detail.htm#14. Accessed 11 Feb 2020. 13.ChanKSLaiSTChuCMTsuiETamCYWongMMet al.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
  <result pre="https://drugs.dxy.cn/drug/153953/detail.htm#14. Accessed 11 Feb 2020. 13.ChanKSLaiSTChuCMTsuiETamCYWongMMet al.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong"/>
  <result pre="Accessed 11 Feb 2020. 13.ChanKSLaiSTChuCMTsuiETamCYWongMMet al.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong Kong"/>
  <result pre="J2003939940614660806 14.ChongYPSongJYSeoYBChoiJPShinHScollab: Rapid Response TeamAntiviral treatment guidelines for Middle East" exact="respiratory" post="syndromeInfect Chemother.20154721222210.3947/ic.2015.47.3.21226483999 15.DailyMed. Lopinavir–ritonavir solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b1caefa-e6a2-42f3-9194-6dc1dd9e6d85. Accessed 12 Feb"/>
  <result pre="21.De FranceschiLFattovichGTurriniFAyiKBrugnaraCManzatoFet al.Hemolytic anemia-induced by ribavirin therapy in patients with" exact="chronic hepatitis" post="C virus infection: role of membrane oxidative damageHepatology200031997100410.1053/he.2000.578910733558 22.RaoYHRibavirin-induced"/>
  <result pre="FranceschiLFattovichGTurriniFAyiKBrugnaraCManzatoFet al.Hemolytic anemia-induced by ribavirin therapy in patients with chronic" exact="hepatitis" post="C virus infection: role of membrane oxidative damageHepatology200031997100410.1053/he.2000.578910733558 22.RaoYHRibavirin-induced"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends202010.5582/bst.2020.0104732074550 24.National Health Commission of the"/>
 </snippets>
</snippetsTree>
